Barclays (LON:BARC) analyst Steven Valiquette maintained a Buy rating on HCA Healthcare (NYSE:HCA) Inc on Friday, setting a price target of $195, which is approximately 15.54% above the present share price of $168.77.
Valiquette expects HCA Healthcare Inc to post earnings per share (EPS) of $1.97 for the first quarter of 2021.
The current consensus among 13 TipRanks analysts is for a Strong Buy rating of shares in HCA Healthcare, with an average price target of $180.75.
The analysts price targets range from a high of $205 to a low of $155.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $13.31 billion and a net profit of $1.32 billion. The company's market cap is $57.11 billion.
According to TipRanks.com, Barclays analyst Steven Valiquette is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.1% and a 56.82% success rate.
HCA Healthcare, Inc. is a health care services company, which engages in operating hospitals, freestanding surgery centers and emergency rooms, and urgent care centers. It offers a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. The company was founded by Dr. Thomas Frist Sr., Dr. Thomas Frist Jr., and Jack Massey in 1968 and is headquartered in Nashville, TN.